PGN 650 I-124

Drug Profile

PGN 650 I-124

Alternative Names: 124I-PGN 650; PGN 650; PGN-650-124-I; PGN-650-I124

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affitech A/S; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Avid Bioservices
  • Class Diagnostic agents; Imaging agents; Monoclonal antibody diagnostics
  • Mechanism of Action Radionuclide imaging enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Solid tumours

Most Recent Events

  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
  • 09 Sep 2013 PGN 650 I-124 is still in phase 0 trials for Solid tumours (Diagnostic imaging) in USA
  • 02 Jul 2012 Phase-0 for Solid tumours (Diagnostic imaging) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top